Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 6/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288888 | 0.86 | CNR2 (0.43) | CNR2POLBHPGDTDP1MMP13 | |
| SCHEMBL6289368 | 0.86 | KDM5A (0.38) | BRD4ADORA2A | |
| SCHEMBL6478088 | 0.82 | PTGER4 (0.41) | POLBHPGDTDP1MMP13CACNA1G | |
| SCHEMBL6289370 | 0.81 | MMP13 (0.46) | MMP13PTGER4 | |
| SCHEMBL6288786 | 0.77 | PLA2G7 (0.35) | MMP13 | |
| SCHEMBL6700843 | 0.77 | POLB (0.44) | CNR2POLBHPGDTDP1PTGER4 | |
| SCHEMBL6813950 | 0.76 | POLB (0.45) | CNR2POLBHPGDTDP1PTGER4 | |
| SCHEMBL6484781 | 0.76 | PTGER4 (0.41) | POLBHPGDMMP13CACNA1GCACNA1H | |
| SCHEMBL6288742 | 0.75 | MAPT (0.49) | — | |
| SCHEMBL6813648 | 0.74 | NAMPT (0.39) | HPGDMMP13CACNA1GCACNA1HCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949651-B2 | Fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | LINCOLN FOODSERVICE PRODUCTS INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2004014375-A2 | FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | CNR2 2917/4885POLB 2737/4885HPGD 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.